Published May 31, 2026 | Version v1
Journal article Open

Paraneoplastic Neuronal Autoantibodies: Neurobiology, Immunopathogenesis, Clinical Spectrum, Diagnosis, and Therapeutic Perspectives — A Descriptive Review

Authors/Creators

Description

Paraneoplastic neuronal autoantibodies (PNAs) constitute a heterogeneous group of immune biomarkers associated with paraneoplastic neurological syndromes (PNSs), which are remote cancer-associated neuroimmunological disorders resulting from antitumor immune responses directed against shared neuronal antigens rather than direct tumor invasion, metastasis, infection, ischemia, metabolic disturbances, or treatment toxicity. Recognition of these antibodies has fundamentally transformed understanding of neuro-oncology by establishing immune-mediated neuronal injury as a major mechanism linking systemic malignancies with central and peripheral nervous system dysfunction.

Paraneoplastic neuronal autoantibodies target intracellular neuronal proteins, cytoplasmic antigens, synaptic proteins, ion channels, membrane receptors, and axonal structures. Classical onconeural antibodies include anti-Hu (ANNA-1), anti-Yo (PCA-1), anti-Ri (ANNA-2), anti-Ma2, anti-CV2/CRMP5, anti-amphiphysin, anti-Tr, anti-Zic4, anti-SOX1, anti-PCA2, and anti-recoverin, whereas neuronal surface antibodies comprise antibodies against N-methyl-D-aspartate receptor (NMDAR), α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), γ-aminobutyric acid receptors (GABAR), leucine-rich glioma-inactivated protein 1 (LGI1), and contactin-associated protein-like 2 (CASPR2). These antibodies exhibit strong associations with systemic malignancies including small-cell lung carcinoma, ovarian cancer, breast cancer, thymoma, testicular germ-cell tumors, and lymphomas.

The pathogenesis involves ectopic neuronal antigen expression by tumors, loss of immune tolerance, antigen presentation, cytotoxic T-cell activation, intrathecal inflammation, blood–brain barrier dysfunction, and progressive neuronal injury. Antibodies directed against intracellular neuronal antigens predominantly reflect T-cell-mediated irreversible neuronal degeneration, whereas neuronal surface antibodies may directly alter receptor signaling and synaptic physiology and therefore demonstrate greater therapeutic reversibility.

Clinically, paraneoplastic neuronal autoantibodies produce a broad spectrum of neurological syndromes including limbic encephalitis, cerebellar degeneration, sensory neuronopathy, encephalomyelitis, opsoclonus–myoclonus syndrome, retinopathy, autonomic dysfunction, peripheral neuropathies, movement disorders, and stiff-person syndrome. Early recognition is particularly important because neurological manifestations frequently precede tumor diagnosis and may represent the earliest indicator of occult malignancy.

This descriptive review comprehensively examines the genetics, molecular genetics, classifications, epidemiology, pathogenesis, neurobiology, neurophysiology, immunopathology, clinical manifestations, diagnostic approaches, differential diagnoses, therapeutic strategies, prognosis, limitations, future directions, and emerging perspectives concerning paraneoplastic neuronal autoantibodies.

Files

TPCJ2026-13-03-1-14.pdf

Files (395.4 kB)

Name Size Download all
md5:0963b944abec437416abcbab3951d270
395.4 kB Preview Download

Additional details

References

  • [1]. Darnell RB, Posner JB. Paraneoplastic Syndromes. New York: Oxford University Press; 2011.
  • [2]. Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75(8):1135-1140. doi:10.1136/jnnp.2003.034447.
  • [3]. Josep Dalmau, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol. 2008;7(4):327-340. doi:10.1016/S1474-4422(08)70060-7.
  • [4]. Graus F, Keime-Guibert F, Reñe R, Benyahia B, Ribalta T, Ascaso C, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001;124(Pt 6):1138-1148.
  • [5]. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous system. N Engl J Med. 2003;349(16):1543-1554. doi:10.1056/NEJMra023009.
  • [6]. Lancaster E, Dalmau J. Neuronal autoantigens—pathogenesis, associated disorders and antibody testing. Lancet Neurol. 2012;11(1):63-74. doi:10.1016/S1474-4422(11)70254-4.
  • [7]. Rosenfeld MR, Dalmau J. Diagnosis and management of paraneoplastic neurologic disorders. Curr Treat Options Oncol. 2013;14(4):528-538.
  • [8]. Graus F, Vogrig A, Muñiz-Castrillo S, Antoine JCG, Desestret V, Dubey D, et al. Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurology. 2021;96(7):335-348.
  • [9]. Honnorat J, Antoine JC. Paraneoplastic neurological syndromes. Orphanet J Rare Dis. 2007;2:22.
  • [10]. Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. Medicine (Baltimore). 1992;71(2):59-72.
  • [11]. Bernal F, Shams'ili S, Rojas I, Sánchez-Valle R, Saiz A, Dalmau J, et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin lymphoma. Neurology. 2003;60(2):230-234.
  • [12]. Shams'ili S, Grefkens J, De Leeuw B, Van den Bent M, Hooijkaas H, Van Pelt E, et al. Paraneoplastic cerebellar degeneration associated with antineuronal antibodies. Brain. 2003;126(Pt 6):1409-1418.
  • [13]. Vernino S, O'Neill BP, Marks RS, O'Fallon JR, Kimmel DW. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro Oncol. 2004;6(1):55-62.
  • [14]. Pittock SJ, Lucchinetti CF. Paraneoplastic and oncologic profiles of patients seropositive for CRMP5-IgG. Neurology. 2003;61(5):703-705.
  • [15]. Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA. CRMP5 neuronal autoimmunity. Ann Neurol. 2001;49(2):146-154.
  • [16]. Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration and anti-Yo antibodies. Neurology. 1992;42(10):1931-1937.
  • [17]. Greenlee JE, Brashear HR. Antibodies to cerebellar Purkinje cells in ovarian carcinoma-associated cerebellar degeneration. Ann Neurol. 1983;14(6):609-613.
  • [18]. Dropcho EJ. Autoimmune central nervous system paraneoplastic disorders. Semin Neurol. 2010;30(3):270-279.
  • [19]. Rojas-Marcos I, Rousseau A, Keime-Guibert F, Rene R, Cartalat-Carel S, Delattre JY, et al. Spectrum of paraneoplastic cerebellar degeneration in anti-Yo patients. Brain. 2003;126(Pt 6):1409-1418.
  • [20]. Voltz R, Gultekin SH, Rosenfeld MR, Gerstner E, Eichen J, Posner JB, et al. A serologic marker of paraneoplastic limbic and brainstem encephalitis in testicular cancer. N Engl J Med. 1999;340(23):1788-1795.
  • [21]. Dalmau J, Bataller L. Clinical and immunological diversity of limbic encephalitis. Lancet Neurol. 2007;6(5):381-391.
  • [22]. Antoine JC, Camdessanché JP. Peripheral nervous system involvement in patients with cancer. Lancet Neurol. 2007;6(1):75-86.
  • [23]. Bataller L, Rosenfeld MR, Graus F, Vilchez JJ, Cheung NK, Dalmau J. Autoantigen diversity in the opsoclonus-myoclonus syndrome. Ann Neurol. 2003;53(3):347-353.
  • [24]. Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibodies. Neurologist. 2003;9(2):76-86.
  • [25]. Graus F, Saiz A, Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS. J Neurol. 2010;257(4):509-517.
  • [26]. Höftberger R, Sabater L, Ortega A, Dalmau J, Graus F. Patient with Homer-3 antibodies and cerebellitis. Neurology. 2013;80(16):1527-1528.
  • [27]. Sabater L, Bataller L, Carpentier AF, Aguirre-Cruz L, Saiz A, Benyahia B, et al. Protein kinase C gamma antibodies in paraneoplastic cerebellar degeneration. Neurology. 2006;66(9):135-136.
  • [28]. Lennon VA, Kryzer TJ, Griesmann GE, O'Suilleabhain PE, Windebank AJ, Woppmann A, et al. Calcium-channel antibodies in Lambert-Eaton syndrome and other paraneoplastic disorders. N Engl J Med. 1995;332(22):1467-1474.
  • [29]. Vincent A, Buckley C, Schott JM, Baker I, Dewar BK, Detert N, et al. Potassium channel antibody-associated encephalopathy. Brain. 2004;127(Pt 3):701-712.
  • [30]. Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, et al. Antibodies to Kv1 potassium channel-complex proteins LGI1 and CASPR2. Brain. 2010;133(Pt 9):2734-2748.
  • [31]. Lai M, Huijbers MGM, Lancaster E, Graus F, Bataller L, Balice-Gordon R, et al. Investigation of LGI1 as antigen in limbic encephalitis. Lancet Neurol. 2010;9(8):776-785.
  • [32]. Josep Dalmau, Tüzün E, Wu HY, Masjuan J, Rossi JE, Voloschin A, et al. Paraneoplastic anti-NMDA receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61(1):25-36.
  • [33]. Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J. Paraneoplastic limbic encephalitis. Brain. 2000;123(Pt 7):1481-1494.
  • [34]. Honnorat J, Cartalat-Carel S, Ricard D, Camdessanché JP, Rogemond V, Chapuis F, et al. Onco-neural antibodies and tumour type determine survival. J Neurol Neurosurg Psychiatry. 2009;80(4):412-416.
  • [35]. Vernino S, Lennon VA. New Purkinje cell antibody (PCA-2). Neurology. 2000;55(5):731-734.
  • [36]. Bataller L, Dalmau J. Paraneoplastic neurologic syndromes: approaches to diagnosis and treatment. Semin Neurol. 2003;23(2):215-224.
  • [37]. Rosenfeld MR, Eichen JG, Wade DF, Posner JB, Dalmau J. Molecular and clinical diversity in paraneoplastic immunity to Ma proteins. Ann Neurol. 2001;50(3):339-348.
  • [38]. Saiz A, Blanco Y, Sabater L, González F, Bataller L, Casamitjana R, et al. Spectrum of neurological syndromes associated with GAD antibodies. Brain. 2008;131(Pt 10):2553-2563.
  • [39]. Honnorat J, Antoine JC, Derrington E, Aguera M, Belin MF. Antibodies to amphiphysin in stiff-person syndrome. Ann Neurol. 1996;39(2):223-232.
  • [40]. Graus F, Delattre JY, Antoine JC, Dalmau J. Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas. Blood. 2004;103(9):3230-3235.
  • [41]. Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic proteins. Neurology. 2011;77(2):179-189.
  • [42]. Höftberger R. Neuroimmunology: an expanding frontier in autoantibody-mediated disorders. Nat Rev Neurol. 2015;11(3):128-129.
  • [43]. Zekeridou A, Lennon VA. Neural autoantibody testing in clinical practice. Neurol Neuroimmunol Neuroinflamm. 2015;2(3):e123.
  • [44]. Dubey D, Pittock SJ, Kelly CR, McKeon A, Lopez-Chiriboga AS, Lennon VA, et al. Autoimmune encephalitis epidemiology and outcomes. Ann Neurol. 2018;83(1):166-177.
  • [45]. McKeon A. Autoimmune movement disorders. Continuum (Minneap Minn). 2016;22(2):522-550.
  • [46]. Vogrig A, Gigli GL, Segatti S, Corazza E, Marini A, Bernardini A, et al. Epidemiology of paraneoplastic neurological syndromes. Brain Behav. 2020;10:e01810.
  • [47]. Zekeridou A, Lennon VA. Paraneoplastic autoimmunity and beyond. Clin Chem Lab Med. 2016;54(11):1711-1719.
  • [48]. Pittock SJ, Yoshikawa H, Ahlskog JE, Tisch SH, Benarroch EE, Kryzer TJ, et al. Glutamic acid decarboxylase autoimmunity. Arch Neurol. 2006;63(2):213-218.
  • [49]. Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med. 2018;378(9):840-851.
  • [50]. Graus F, Dalmau J. Paraneoplastic neurological syndromes: diagnosis and treatment. Curr Opin Neurol. 2012;25(6):795-801.
  • [51]. Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, Cortese I, Dale RC, Gelfand JM, Geschwind M, Glaser CA, Honnorat J, Höftberger R, Iizuka T, Irani SR, Lancaster E, Leypoldt F, Prüss H, Rae-Grant A, Reindl M, Rosenfeld MR, Rostásy K, Saiz A, Venkatesan A, Vincent A, Wandinger KP, Waters P, Dalmau J. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391-404. doi:10.1016/S1474-4422(15)00401-9.
  • [52]. Irani SR, Vincent A. Autoimmune encephalitis—new awareness, challenging questions. Dis Model Mech. 2011;4(5):604-608. doi:10.1242/dmm.007146.
  • [53]. Leypoldt F, Wandinger KP. Paraneoplastic neurological syndromes. Clin Exp Immunol. 2014;175(3):336-348.
  • [54]. Pittock SJ, Kryzer TJ, Lennon VA. Paraneoplastic antibodies coexist and predict cancer, not neurological syndrome. Ann Neurol. 2004;56(5):715-719.
  • [55]. Antoine JC, Honnorat J. Paraneoplastic neuropathies. Curr Opin Neurol. 2003;16(5):633-638.
  • [56]. Rees JH. Paraneoplastic syndromes: when to suspect, how to confirm, and how to manage. J Neurol Neurosurg Psychiatry. 2004;75(Suppl 2):ii43-ii50.
  • [57]. Graus F, Saiz A, Dalmau J. GAD antibodies in neurological disorders—insights and controversies. Lancet Neurol. 2020;19(2):104-106.
  • [58]. Rosenfeld MR, Wong E, Dalmau J, Manley G, Posner JB. Clonal cytotoxic T-cell populations in paraneoplastic neurological syndromes. Ann Neurol. 1998;43(2):156-162.
  • [59]. Voltz R. Paraneoplastic neurological syndromes: an update on diagnosis, pathogenesis, and therapy. Lancet Neurol. 2002;1(5):294-305.
  • [60]. Tanaka K, Tanaka M, Onodera O, Tsuji S. Clinical spectrum of anti-Ma2-associated encephalitis. J Neurol Neurosurg Psychiatry. 2003;74(6):827-829.
  • [61]. Bataller L, Wade DF, Fuller GN, Rosenfeld MR, Dalmau J. Cerebellar degeneration and anti-Tr antibodies in Hodgkin lymphoma. Neurology. 2002;58(2):230-234.
  • [62]. Sabater L, Höftberger R, Boronat A, Saiz A, Dalmau J, Graus F. Neurochondrin antibodies in autoimmune cerebellar degeneration. Neurology. 2016;86(12):1136-1143.
  • [63]. Höftberger R, Titulaer MJ, Sabater L, Dome B, Rózsás A, Hegedus B, et al. Encephalitis and GABAB receptor antibodies in small-cell lung cancer. Neurology. 2013;81(17):1500-1506.
  • [64]. Boronat A, Sabater L, Saiz A, Dalmau J, Graus F. GABAA receptor antibodies in autoimmune neurological disease. Neurology. 2011;76(9):795-800.
  • [65]. Armangue T, Leypoldt F, Málaga I, Raspall-Chaure M, Marti I, Nichter C, et al. Herpes simplex virus encephalitis as trigger of autoimmune encephalitis. Neurology. 2014;83(10):919-926
  • [66]. Dubey D, McKeon A, Zekeridou A, Flanagan EP, Lennon VA, Klein CJ, et al. Autoimmune encephalitis epidemiology and comparison with infectious encephalitis. Ann Neurol. 2018;83(1):166-177.
  • [67]. Vogrig A, Muñiz-Castrillo S, Joubert B, Honnorat J. Pathophysiology of paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2020;91(7):764-772.
  • [68]. Zekeridou A, McKeon A, Lennon VA. Frequency of synaptic and intracellular neuronal antibodies in paraneoplastic disorders. Neurol Neuroimmunol Neuroinflamm. 2019;6(6):e585.
  • [69]. Vogrig A, Gigli GL, Segatti S, Corazza E, Marini A, Bernardini A, et al. Clinical and epidemiological spectrum of paraneoplastic neurological syndromes. Brain Behav. 2020;10:e01810.
  • [70]. Dalmau J, Rosenfeld MR. Autoimmune encephalitis update. Neuro Oncol. 2014;16(6):771-778.